[Maturity onset diabetes of the young (MODY) - screening, diagnostic and therapy]

Wien Klin Wochenschr. 2016 Apr:128 Suppl 2:S204-7. doi: 10.1007/s00508-015-0938-9.
[Article in German]

Abstract

Maturity onset diabetes of the young (MODY) is a group of monogenetic diabetes types affecting up to 2% all known diabetics. Transcription factor MODY (HNF1α, HNF4α), the most frequent forms of MODY, allow treatment with sulfonylureas, mutations of glucokinase (GCK-MODY) usually do not require any therapy. Especially in younger patients correct diagnosis of MODY often results in discontinuation of insulin therapy and initiation of a sulfonylurea. Accordingly, in patients with diabetes onset below age of 25 years, with a positive family history for diabetes and negative autoantibodies screening for MODY is recommended.

Keywords: Diabetes; Glucokinase mutation; Monogenetic; Transcription factors.

Publication types

  • Review

MeSH terms

  • Austria
  • Diabetes Mellitus, Type 2 / diagnosis*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Evidence-Based Medicine
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Mass Screening / standards*
  • Practice Guidelines as Topic*
  • Sulfonylurea Compounds / administration & dosage*
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Sulfonylurea Compounds